Search

Your search keyword '"Silengo, Shawn"' showing total 12 results
Start Over Author "Silengo, Shawn"
12 results on '"Silengo, Shawn"'

2. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Author

Osorio, Jorge E, primary, Velez, Ivan D, additional, Thomson, Cynthia, additional, Lopez, Liliana, additional, Jimenez, Alejandra, additional, Haller, Aurelia A, additional, Silengo, Shawn, additional, Scott, Jaclyn, additional, Boroughs, Karen L, additional, Stovall, Janae L, additional, Luy, Betty E, additional, Arguello, John, additional, Beatty, Mark E, additional, Santangelo, Joseph, additional, Gordon, Gilad S, additional, Huang, Claire Y-H, additional, and Stinchcomb, Dan T, additional

Published
2014
Full Text
View/download PDF

3. Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)

Author

Huang, Claire Y.-H., primary, Kinney, Richard M., additional, Livengood, Jill A., additional, Bolling, Bethany, additional, Arguello, John J., additional, Luy, Betty E., additional, Silengo, Shawn J., additional, Boroughs, Karen L., additional, Stovall, Janae L., additional, Kalanidhi, Akundi P., additional, Brault, Aaron C., additional, Osorio, Jorge E., additional, and Stinchcomb, Dan T., additional

Published
2013
Full Text
View/download PDF

9. Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes

Author

Bryant, Juliet E., primary, Calvert, Amanda E., additional, Mesesan, Kyeen, additional, Crabtree, Mary B., additional, Volpe, Katharine E., additional, Silengo, Shawn, additional, Kinney, Richard M., additional, Huang, Claire Y.-H., additional, Miller, Barry R., additional, and Roehrig, John T., additional

Published
2007
Full Text
View/download PDF

11. Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus.

Author

Y.-H. Huang, Claire, Silengo, Shawn J., Whiteman, Melissa C., and Kinney, Richard M.

Subjects
*DENGUE, *ARBOVIRUS diseases, *VACCINES, *WEST Nile virus, *VIROLOGY
Abstract

Chimeric dengue serotype 2/West Nile (D2/WN) viruses expressing prM-E of WN NY99 virus in the genetic background of wild-type D2 16681 virus and two candidate D2 PDK-53 vaccine variants (PDK53-E and PDK53-V) were engineered. The viability of the D2/WN viruses required incorporation of the WN virus-specific signal sequence for prM. Introduction of two mutations at M-58 and E-191 in the chimeric cDNA clones further improved the viability of the chimeras constructed in all three D2 carriers. Two D2/WN chimeras (D2/WN-E2 and -V2) engineered in the backbone of the PDK53-E and -V viruses retained all of the PDK-53 vaccine characteristic phenotypic markers of attenuation and were immunogenic in mice and protected mice from a high-dose 107 PFU challenge with wild-type WN NY99 virus. This report further supports application of the genetic background of the D2 PDK-53 virus as a carrier for development of live-attenuated, chimeric flavivirus vaccines in general and the development of a chimeric D2/WN vaccine virus against WN disease in particular. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

12. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.

Author

David A. Stein, Claire Y.-H. Huang, Shawn Silengo, Adams Amantana, Stacy Crumley, Robert E. Blouch, Patrick L. Iversen, Richard M. Kinney, Stein, David A, Huang, Claire Y-H, Silengo, Shawn, Amantana, Adams, Crumley, Stacy, Blouch, Robert E, Iversen, Patrick L, and Kinney, Richard M

Subjects
GEL permeation chromatography, CHROMATOGRAPHIC analysis, SEPHAROSE, RODENTS
Abstract

Objectives: To determine the antiviral activity of phosphorodiamidate morpholino oligomers (PMO) and peptide-conjugated PMO (PPMO) in AG129 mice infected with dengue 2 virus (DENV-2).Methods: Antisense PMO and PPMO were designed against the 5' terminal region (5'SL) or the 3'-cyclization sequence region (3'CS) of DENV genomic RNA and administered to AG129 mice before and/or after infection with DENV-2. In addition, cell culture evaluations designed to determine optimum PPMO length, and pharmacokinetic and toxicity analysis of PPMO were also carried out.Results: Mock-treated AG129 mice lived for 9-17 days following intraperitoneal (ip) infection with 10(4)-10(6) pfu of DENV-2 (strain New Guinea C). Intraperitoneal administration of 5'SL or 3'CS PPMO before and after DENV infection produced an increase in the average survival time of up to 8 days. Animals receiving only post-infection PPMO treatment did not benefit significantly. Cell culture studies showed that PPMO of 22-24 bases long produced substantially higher DENV titre reductions than did PPMO that were either shorter or longer. Pharmacokinetic and toxicology analysis with non-infected animals showed that nine consecutive once-daily ip treatments of 10 mg/kg PPMO resulted in high concentrations of PPMO in the liver and caused little impact on overall health.Conclusions: The data indicate that PPMO had considerable antiviral efficacy against DENV-2 in the AG129 mouse model and that PPMO treatment early in the course of an infection was critical to extending the survival times of DENV-2-infected mice in the AG129 model system. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results